Ask AI

Precision Therapeutics for NF1-Associated Tumors: Improved Outcomes Through Targeted MEK Inhibition

Learn more about the expert recommended optimal management of patients with NF1-associated tumors from this on-demand webcast with downloadable slides and an expert-authored commentary with answers to frequently asked questions.

Share

Program Content

No activities added yet

No activities added yet

No activities added yet

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC

Supporters

Supported by educational grants from Alexion Pharmaceuticals and SpringWorks Therapeutics, Inc.

Alexion Pharmaceuticals

SpringWorks Therapeutics, Inc.